Pupfish Selenium Drain Studies Sample Clauses

Pupfish Selenium Drain Studies. This is the first year of conducting this mitigation measure as part of the Regional Water Quality Control Board’s conditional agricultural waiver. All monitoring locations have been identified and all equipment has been placed in the field. Additional soil sampling, monitoring, and drain cleaning activities are taking place. Task 20 Pupfish Construction and Maintenance – IID is working on a desert pupfish drain interconnection plan outline to be presented to the wildlife agencies the following week for review and input. Additionally, two to three staff members will be trained in pupfish trapping starting the following week. Task 24 Air Quality – SCS Engineers have started operating the air quality program air stations, which has resolved numerous issues that were taking place under management with the previous consultants. Most stations are now running at 100 percent. Surface roughening contractors are working on five projects around the south end of the Salton Sea for a total of 625 project acres to be completed by the end of summer 2019. IID’s Energy Department is working to locate and install three additional round-shot cameras. Potential camera locations are: Salton City, New River West, and Bombay Beach. The Anza Xxxxxxx camera will be removed in July due to high temperatures. The 2018/2019 Proactive Dust Control Plan and 2017/2018 Emissions Inventory documents were presented to the IID Board as information items on June 4. IID will be meeting with the Imperial County Air Pollution Control District (ICAPCD) to brief them on the documents before they are finalized. Copies of the 2019 Air Quality Mitigation Brochure were provided. This is the first of two to three new brochures for the public. A larger more technical document will also be released most likely in August. The air quality webpage has also been updated with the new documents. Xxxxxxx Xxxxx of the Pacific Institute sent an inquiry by email to Xxx. Xxxxx regarding restricting access to exposed playa. Xxx. Xxxxx stated that IID has installed no trespassing signs on IID property and has looked into areas where gates can be used but anything on private property would require working with those land owners. Alternate Chair Xxxxxx asked that when IID meets with CDFW regarding the drain interconnection project that those plans also be shared with the Department of Water Resources. Commissioner Xxxxxx asked if the JPA has a contract with ICAPCD for emissions inventory. Alternate Commissioner Xxxxxx...
Sample 1Sample 2
AutoNDA by SimpleDocs
Pupfish Selenium Drain Studies. There is ongoing monitoring for tasks 1 and 2 as part of the salinity monitoring. IID is coordinating with the Regional Water Quality Control Board as part of the monitoring effort.
Sample 1Sample 2
Pupfish Selenium Drain Studies. IID continues to collect data as part of its selenium drain workplan and Quality Assurance Project Plan (QAPP) per its Ag Waiver from the Regional Water Quality Control Board. Due to field constraints, IID made minor revisions to its workplan and QAPP that were approved to expand the list of drains for monitoring and give IID more time to complete the project, which is expected to be completed by June 2025.
Sample 1

Related to Pupfish Selenium Drain Studies

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • ROAD WORK PHASE APPROVAL Purchaser shall obtain written approval from the Contract Administrator upon completion of each of the following phases of road work:  Drainage installation  Subgrade compaction  Rock compaction SUBSECTION RESTRICTIONS

  • Programming Phase 2.2.1.2. Schematic Design Phase: 2.2.1.3. Design Development Phase:

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Development Area 10.4. The Development Area shall encompass all Deposits to be produced.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Biological Samples If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee Biological Samples (“Biological Samples”). 12.2.

  • Trials The Ship shall run the following test and trials:

  • Transporting Students Teachers shall not be required to transport a student in a private vehicle on behalf of the school.

Time is Money Join Law Insider Premium to draft better contracts faster.